{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:56:14Z","timestamp":1767135374879,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":60,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd003232.pub2","type":"reference-entry","created":{"date-parts":[[2008,6,30]],"date-time":"2008-06-30T07:24:52Z","timestamp":1214810692000},"source":"Crossref","is-referenced-by-count":10,"title":["Interventions for renal vasculitis in adults"],"prefix":"10.1002","author":[{"given":"Giles","family":"Walters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narelle S","family":"Willis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,16]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD003232.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/qjmed\/90.6.401","article-title":"Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis","volume":"90","author":"Adu","year":"1997","journal-title":"Qjm"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0272-6386(12)80699-8","article-title":"A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group","volume":"20","author":"Cole","year":"1992","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub2-BIB3|cit3","first-page":"S127","article-title":"Lymphocytapheresis (LCP) in rapidly progressive glomerulonephritis (RPGN) a comparison with steroid pulse therapy [abstract]","volume":"3 Suppl","author":"Furuta","year":"1997","journal-title":"Nephrology"},{"issue":"9123","key":"10.1002\/14651858.CD003232.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(05)77809-0","article-title":"Lymphocytapheresis to treat rapidly progressive glomerulonephritis: a randomised comparison with steroid-pulse treatment","volume":"352","author":"Furuta","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub2-BIB5|cit5","first-page":"1","article-title":"Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multi-center study","volume":"29","author":"Glockner","year":"1988","journal-title":"Clinical Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD003232.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis","volume":"40","author":"Guillevin","year":"1997","journal-title":"Arthritis & Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD003232.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q","article-title":"Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study","volume":"41","author":"Haubitz","year":"1998","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.bor.0000160777.28259.c2","article-title":"Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies","volume":"17","author":"Goek","year":"2005","journal-title":"Current Opinion in Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003232.pub2-BIB10|cit10","series-title":"XXXV Congress of the European Renal Association European Dialysis & Transplant Association; 1998 Jun 6-9; Rimini (Italy)","first-page":"106","article-title":"European randomised trials in ANCA-associated systemic vasculitis: a progressive report [abstract]","author":"Jayne","year":"1998"},{"issue":"Programs & Abst","key":"10.1002\/14651858.CD003232.pub2-BIB11|cit11","first-page":"2A","article-title":"Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis [abstract]","volume":"13","author":"Gaskin","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD003232.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003232.pub2-BIB13|cit13","series-title":"XXXV Congress of the European Renal Association European Dialysis & Transplant Association; 1998 Jun 6-9; Rimini (Italy)","first-page":"106","article-title":"European randomised trials in ANCA-associated systemic vasculitis: a progressive report [abstract]","author":"Jayne","year":"1998"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub2-BIB14|cit14","first-page":"587","article-title":"Therapeutic plasma exchange in the treatment of rapidly progressive glomerulonephritis","volume":"6","author":"Mauri","year":"1985","journal-title":"Plasma Therapy & Transfusion Technology"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/ki.1991.272","article-title":"Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies","volume":"40","author":"Pusey","year":"1991","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD003232.pub2-BIB16|cit16","series-title":"Proceedings of the European Dialysis & Transplant Association","first-page":"493","article-title":"Treatment of idiopathic acute crescentic glomerulonephritis by immunodepression and plasma-exchanges. A prospective randomised study","author":"Rifle","year":"1981"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group","volume":"335","author":"Stegeman","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/039139889902200205","article-title":"Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study","volume":"22","author":"Stegmayr","year":"1999","journal-title":"International Journal of Artificial Organs"},{"key":"10.1002\/14651858.CD003232.pub2-BIB19|cit19","series-title":"XXXV Congress of the European Renal Association European Dialysis & Transplant Association; 1998 Jun 6-9; Rimini (Italy)","first-page":"294","article-title":"Plasma exchange versus immunoadsorption in the treatment of rapidly progressive glomerulonephritis (RPG). A multi-center study [abstract]","author":"Stegmayr","year":"1998"},{"issue":"8","key":"10.1002\/14651858.CD003232.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Groot","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.bor.0000160777.28259.c2","article-title":"Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies","volume":"17","author":"Goek","year":"2005","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1002\/14651858.CD003232.pub2-BIB22|cit22","first-page":"263","article-title":"Treatment of rapidly progressive glomerulonephritis by plasma exchange and methylprednisolone pulses. A prospective randomized trial of cyclophosphamide. Interim analysis. The French Cooperative Group","volume":"337","author":"Rifle","year":"1990","journal-title":"Progress in Clinical & Biological Research"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.bor.0000160777.28259.c2","article-title":"Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies","volume":"17","author":"Goek","year":"2005","journal-title":"Current Opinion in Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD003232.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-142-8-200505030-00011","article-title":"Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study","volume":"142","author":"Merkel","year":"2005","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD003232.pub2-BIB25|cit25","unstructured":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase I\/II trial of TNFR:Fc (Etanercept) in patients with Wegener's Granulomatosis www.clinicaltrials.gov 2004"},{"issue":"7","key":"10.1002\/14651858.CD003232.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/art.21117","article-title":"Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)","volume":"52","author":"Seo","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/art.20938","article-title":"A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis","volume":"52","author":"Stone","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD003232.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/art.11075","article-title":"Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial","volume":"48","author":"Stone","year":"2003","journal-title":"Arthritis & Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub2-BIB30|cit29","first-page":"351","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"325","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub2-BIB29|cit30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0197-2456(02)00209-X","article-title":"Design of the Wegener's Granulomatosis Etanercept Trial (WGET)","volume":"23","year":"2002","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD003232.pub2-BIB32|cit31","first-page":"153","article-title":"Randomised controlled trial of daily oral versus pulse cyclophosphaminde for induction of remission in ANCA-associated systemic vasculitis [abstract]","volume":"28","author":"Groot","year":"2005","journal-title":"Kidney & Blood Pressure Research"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub2-BIB31|cit32","first-page":"64","article-title":"Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis--preliminary single center experience","volume":"105","author":"Rihova","year":"2004","journal-title":"Prague Medical Report"},{"key":"10.1002\/14651858.CD003232.pub2-BIB33|cit33","unstructured":"Guillevin L Treatment of necrotizing vasculitides for patients older than 65 years comparison of two strategies combining steroids with or without Immunosuppressants ClinicalTrials.gov 2005"},{"key":"10.1002\/14651858.CD003232.pub2-BIB34|cit34","unstructured":"EUVAS Mycophenolate mofetil versus azathioprine for maintenance therapy in ANCA associated systemic vasculitis. International Mycophenolate mofetil protocol to reduce outbreaks of vasculitides www.clinicaltrials.gov 2003"},{"key":"10.1002\/14651858.CD003232.pub2-BIB35|cit35","unstructured":"EUVAS The prevention of relapses of Wegeners granulomatosis by the elimination of nasal S aureus carriage: a multicentre randomized study www.vasculitis.org 1998"},{"key":"10.1002\/14651858.CD003232.pub2-BIB36|cit36","unstructured":"Guillevin L RATTRAP Infiliximab versus Rituximab in systemic necrotizing vasculitides www.clinicaltrials.gov 2004"},{"key":"10.1002\/14651858.CD003232.pub2-BIB37|cit37","unstructured":"Stone JH Specks U Rituximab therapy for the induction of remission and tolerance in ANCA associated vasculitis www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD003232.pub2-BIB38|cit38","article-title":"Randomised trial of prolonged remission-maintenance therapy in systemic vasculitis","author":"EUVAS","year":"2003","journal-title":"www.vasculitis.org"},{"key":"10.1002\/14651858.CD003232.pub2-BIB39|cit39","article-title":"An international, randomised, open label trial comparing a rituximab based regimen with a standard cyclophosphamide\/azathioprine regimen in the treatment of active, \u2018generalised\u2019 ANCA associated vasculitis","author":"Jayne","year":"2005","journal-title":"www.vasculitis.org"},{"key":"10.1002\/14651858.CD003232.pub2-BIB40|cit40","unstructured":"Stassen PM Stegeman CA Mycophenolate mofetil for treatment of relapses of Wegeners disease or microscopic polyangiitis www.clinicaltrials.gov"},{"issue":"5","key":"10.1002\/14651858.CD003232.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000167998","article-title":"Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis","volume":"9","author":"Bolton","year":"1989","journal-title":"American Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003232.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jama.298.6.655","article-title":"Treatment of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"298","author":"Bosch","year":"2007","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD003232.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/ndt\/16.10.2018","article-title":"The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review","volume":"16","author":"Groot","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6964","key":"10.1002\/14651858.CD003232.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"issue":"7414","key":"10.1002\/14651858.CD003232.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD003232.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0025-6196(11)63594-5","article-title":"Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group","volume":"72","author":"Jayne","year":"1997","journal-title":"Mayo Clinic Proceedings"},{"issue":"7","key":"10.1002\/14651858.CD003232.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"Qjm"},{"key":"10.1002\/14651858.CD003232.pub2-BIB48|cit48","first-page":"341","article-title":"Renal and systemic vasculitis","volume-title":"Comprehensive clinical nephrology","author":"Jennette","year":"2003"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1440-1797.2001.00052.x","article-title":"Is there a role for plasma exchange in rapidly progressive glomerulonephritis?","volume":"6","author":"Kerr","year":"2001","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD003232.pub2-BIB50|cit50","series-title":"Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia)","article-title":"Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE","author":"Lefebvre","year":"1996"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000188012","article-title":"Rapidly progressive glomerulonephritis: what should be first-line therapy?","volume":"67","author":"Levey","year":"1994","journal-title":"Nephron"},{"issue":"7962","key":"10.1002\/14651858.CD003232.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0140-6736(76)93089-0","article-title":"Immunosuppression and plasma exchange in the treatment of Goodpasture's syndrome","volume":"1","author":"Lockwood","year":"1976","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003232.pub2-BIB53|cit53","unstructured":"United States Cochrane Center Master list of journals being searched http:\/\/apps1.jhsph.edu\/cochrane\/masterlist.asp"},{"issue":"9054","key":"10.1002\/14651858.CD003232.pub2-BIB54|cit54","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0140-6736(05)60198-5","article-title":"Mycophenolate mofetil for systemic vasculitis and IgA nephropathy","volume":"349","author":"Nowack","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003232.pub2-BIB55|cit55","first-page":"331","article-title":"Antiglomerular basement membrane disease and goodpasture's syndrome","volume-title":"Comprehensive clinical nephrology","author":"Phelps","year":"2003"},{"key":"10.1002\/14651858.CD003232.pub2-BIB56|cit56","unstructured":"Willis NS Mitchell R Higgins GY Webster AC Craig JC Cochrane Renal Group About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2008, Issue 1. Art. No.: RENAL"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub2-BIB57|cit57","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/oxfordjournals.ndt.a091855","article-title":"Plasma exchange and immunosuppression for rapidly progressive glomerulonephritis: prognosis and complications","volume":"4","author":"Rondeau","year":"1989","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003232.pub2-BIB58|cit58","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/rheumatology\/41.5.589","article-title":"Sulphamethoxazole-trimethoprim in the treatment of limited paranasal Wegener's granulomatosis","volume":"41","author":"Sangle","year":"2002","journal-title":"Rheumatology"},{"issue":"9051","key":"10.1002\/14651858.CD003232.pub2-BIB59|cit59","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0140-6736(97)80118-3","article-title":"Primary systemic vasculitis","volume":"349","author":"Savage","year":"1997","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub2-BIB60|cit60","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00041552-200103000-00009","article-title":"Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"10","author":"Tervaert","year":"2001","journal-title":"Current Opinion in Nephrology and Hypertension"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003232.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T00:00:00Z","timestamp":1443052800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003232.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:17:48Z","timestamp":1628529468000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003232.pub2"}},"subtitle":[],"editor":[{"given":"Giles","family":"Walters","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2008,7,16]]},"references-count":60,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003232.pub2","relation":{},"subject":[],"published":{"date-parts":[[2008,7,16]]}}}